Facebook
Twitter
LinkedIn
Forward
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Bladder Cancer
Advances in the Treatment of Muscle-Invasive Bladder Cancer
With an increasing number of treatment options for muscle-invasive urothelial bladder cancer available, it is important for physicians to understand these various treatments and identify which option is likely to bring the greatest benefit to a specific patient. Bladder-preserving treatment approaches involving multimodal therapies may be the best option for improving outcomes in select patients. Additionally, with five new systemic therapies approved in the past year, the treatment landscape for metastatic or locally advanced bladder cancer has become increasingly complex requiring education on treatment selection and sequencing.
Target Audience
This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Describe which patients with muscle-invasive bladder cancer are candidates for bladder-sparing treatment and how multimodal approaches may be used.
- Identify appropriate first-line systemic therapy options for patients with metastatic or locally advanced bladder cancer, and review how patient characteristics can guide therapy choice.
- Discuss the use of subsequent-line therapy for bladder cancer, including recently approved checkpoint inhibitors.
Thomas Pugh, MD
University of Colorado Cancer Center
Thomas Flaig, MD
University of Colorado Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below discloses no relevant financial relationships:
Thomas Flaig, MD
Thomas Pugh, MD
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kim Bayer; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD (employed by NCCN until October 30, 2017)
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options
Katie Pierce
Boston Scientific Corporation – Equity Interest/Stock Options
Pfizer Inc. – Equity Interest/Stock Options
The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Lisa Gurski, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.75 hour of Category 1 credit for completing this activity.
Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 0.75 contact hour.
Pharmacists
| National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: 0836-0000-18-103-H01-P
Available Credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing